SCHEMBL1978409

SCHEMBL1978409

CC(C)(CI)CI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13352050 0.82 CYP2D6 (0.38)
SCHEMBL1906572 0.79
SCHEMBL18329269 0.79
SCHEMBL22581270 0.77
SCHEMBL6275726 0.76
SCHEMBL1400002 0.76
SCHEMBL2612612 0.76 CYP2D6 (0.33)
SCHEMBL77943 0.74
SCHEMBL16622888 0.73
SCHEMBL23544062 0.71 CYP2D6 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573085-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS Glenmark Pharmaceuticals Limited (IN) 2025-06-25 EP disclosed
CN-119546587-A Substituted pyridone compounds as CBL-B inhibitors 格兰玛克制药有限公司 2025-02-28 CN disclosed
WO-2024062363-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS CBL-B INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2024-03-28 WO disclosed
WO-2024038378-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2024-02-22 WO disclosed
WO-2024038378-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2024-02-22 WO disclosed
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS Madera Therapeutics, LLC 2023-10-26 US disclosed
CN-109666158-B Hybrid dynamic polymer and application thereof 厦门逍扬运动科技有限公司 2023-04-07 CN disclosed
EP-2738156-B1 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS KBP BIOSCIENCES USA INC (US) 2018-01-03 EP disclosed
US-9365499-B2 9-aminomethyl substituted tetracycline compounds KBP BIOSCIENCES CO., LTD. (CN) 2016-06-14 US disclosed
US-9365499-B2 9-aminomethyl substituted tetracycline compounds KBP BIOSCIENCES CO., LTD. (CN) 2016-06-14 US disclosed
US-20110244368-A1 NORBORNENE-TYPE POLYMERS HAVING QUATERNARY AMMONIUM FUNCTIONALITY PROMERUS LLC (US) 2011-10-06 US disclosed
US-20110143260-A1 NORBORNENE-TYPE POLYMERS HAVING QUATERNARY AMMONIUM FUNCTIONALITY PROMERUS LLC (US) 2011-06-16 US disclosed
US-20070142300-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease MERCK SHARP & DOHME LLC 2007-06-21 US disclosed
US-7186747-B2 Compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2007-03-06 US disclosed
US-7173057-B2 Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus SCHERING CORPORATION (US) 2007-02-06 US disclosed
US-6242651-B1 IN A HIGH YIELD BY REACTING DIHALOALKANE WITH ALKYLAMINE WHILE INHIBITING FORMATION OF UNFAVORABLE BY-PRODUCTS SUCH AS CYCLIC DIALKYLDIAMINE AND TRIALKYLALKANETRIAMINE MITSUI CHEMICALS, INC. (JP) 2001-06-05 US disclosed
EP-0618900-B1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS KNOLL AG (DE) 1997-03-12 EP disclosed
US-5519034-A ANALGESICS THE BOOTS COMPANY PLC (GB) 1996-05-21 US disclosed
EP-0618900-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. BOOTS CO PLC (GB) 1994-10-12 EP disclosed
WO-1993013073-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1993-07-08 WO disclosed